<?xml version='1.0' encoding='utf-8'?>
<document id="31313296"><sentence text="Concomitant Intake of Coca-Cola to Manage the Drug-Drug Interaction Between Velpatasvir and Omeprazole Studied in Healthy Volunteers."><entity charOffset="92-102" id="DDI-PubMed.31313296.s1.e0" text="Omeprazole" /></sentence><sentence text="We aimed to evaluate the effect of the acid beverage Coca-Cola on the pharmacokinetics of velpatasvir (VEL) when given with omeprazole"><entity charOffset="90-101" id="DDI-PubMed.31313296.s2.e0" text="velpatasvir" /><entity charOffset="124-134" id="DDI-PubMed.31313296.s2.e1" text="omeprazole" /><pair ddi="false" e1="DDI-PubMed.31313296.s2.e0" e2="DDI-PubMed.31313296.s2.e0" /><pair ddi="false" e1="DDI-PubMed.31313296.s2.e0" e2="DDI-PubMed.31313296.s2.e1" /></sentence><sentence text=" This was an open-label, randomized, crossover trial in 11 healthy adults" /><sentence text=" A single dose of sofosbuvir/velpatasvir (SOF/VEL) 400/100 mg was administered alone (reference) or with omeprazole 40 mg once daily with water (intervention I); in the intervention II arm, omeprazole 40 mg was combined with 250 mL of Coca-Cola"><entity charOffset="18-28" id="DDI-PubMed.31313296.s4.e0" text="sofosbuvir" /><entity charOffset="29-40" id="DDI-PubMed.31313296.s4.e1" text="velpatasvir" /><entity charOffset="42-45" id="DDI-PubMed.31313296.s4.e2" text="SOF" /><entity charOffset="105-115" id="DDI-PubMed.31313296.s4.e3" text="omeprazole" /><entity charOffset="190-200" id="DDI-PubMed.31313296.s4.e4" text="omeprazole" /><pair ddi="false" e1="DDI-PubMed.31313296.s4.e0" e2="DDI-PubMed.31313296.s4.e0" /><pair ddi="false" e1="DDI-PubMed.31313296.s4.e0" e2="DDI-PubMed.31313296.s4.e1" /><pair ddi="false" e1="DDI-PubMed.31313296.s4.e0" e2="DDI-PubMed.31313296.s4.e2" /><pair ddi="false" e1="DDI-PubMed.31313296.s4.e0" e2="DDI-PubMed.31313296.s4.e3" /><pair ddi="false" e1="DDI-PubMed.31313296.s4.e0" e2="DDI-PubMed.31313296.s4.e4" /><pair ddi="false" e1="DDI-PubMed.31313296.s4.e1" e2="DDI-PubMed.31313296.s4.e1" /><pair ddi="false" e1="DDI-PubMed.31313296.s4.e1" e2="DDI-PubMed.31313296.s4.e2" /><pair ddi="false" e1="DDI-PubMed.31313296.s4.e1" e2="DDI-PubMed.31313296.s4.e3" /><pair ddi="false" e1="DDI-PubMed.31313296.s4.e1" e2="DDI-PubMed.31313296.s4.e4" /><pair ddi="false" e1="DDI-PubMed.31313296.s4.e2" e2="DDI-PubMed.31313296.s4.e2" /><pair ddi="false" e1="DDI-PubMed.31313296.s4.e2" e2="DDI-PubMed.31313296.s4.e3" /><pair ddi="false" e1="DDI-PubMed.31313296.s4.e2" e2="DDI-PubMed.31313296.s4.e4" /><pair ddi="false" e1="DDI-PubMed.31313296.s4.e3" e2="DDI-PubMed.31313296.s4.e3" /><pair ddi="false" e1="DDI-PubMed.31313296.s4.e3" e2="DDI-PubMed.31313296.s4.e4" /></sentence><sentence text=" Geometric mean ratios (GMRs) were calculated for VEL area under the concentration-time curve from zero to infinity (AUC0-inf ) and maximum plasma concentration (Cmax )" /><sentence text=" VEL exposure was reduced by 26" /><sentence text="7% when SOF/VEL was coadministered with omeprazole vs"><entity charOffset="40-50" id="DDI-PubMed.31313296.s7.e0" text="omeprazole" /><entity charOffset="8-17" id="DDI-PubMed.31313296.s7.e1" text="SOF" /><pair ddi="false" e1="DDI-PubMed.31313296.s7.e1" e2="DDI-PubMed.31313296.s7.e1" /><pair ddi="false" e1="DDI-PubMed.31313296.s7.e1" e2="DDI-PubMed.31313296.s7.e0" /></sentence><sentence text=" reference: GMRs (90% confidence interval (CI)) were 73" /><sentence text="3% (55" /><sentence text="6-96" /><sentence text="8) and 69" /><sentence text="1% (52" /><sentence text="3-91" /><sentence text="2) for AUC0-inf and Cmax , respectively" /><sentence text=" Intake of SOF/VEL with Coca-Cola compensated for the interaction with omeprazole and resulted in a higher VEL exposure"><entity charOffset="71-81" id="DDI-PubMed.31313296.s15.e0" text="omeprazole" /><entity charOffset="11-20" id="DDI-PubMed.31313296.s15.e1" text="SOF" /><pair ddi="false" e1="DDI-PubMed.31313296.s15.e1" e2="DDI-PubMed.31313296.s15.e1" /><pair ddi="false" e1="DDI-PubMed.31313296.s15.e1" e2="DDI-PubMed.31313296.s15.e0" /></sentence><sentence text=" GMRs (90% CI) were 161" /><sentence text="6% (122" /><sentence text="4-213" /><sentence text="3) for AUC0-inf and 143" /><sentence text="9% (109" /><sentence text="0-190" /><sentence text="0) for Cmax " /><sentence text=" Therefore, Coca-Cola can be used to overcome the drug-drug interaction between VEL and omeprazole"><entity charOffset="88-98" id="DDI-PubMed.31313296.s23.e0" text="omeprazole" /></sentence><sentence text="" /></document>